Efgartigimod Treatment Increases Spending for CIDP Patients

Using an integrated delivery network perspective model to project costs expected by introducing efgartigimod alfa (Vyvgart; Argenx), a neonatal Fc receptor antagonist, in a portion of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (SCIG) or intravenous IG (IVIG) found that introducing efgartigimod alfa as a treatment option would result in substantially increased spending in the treatment of CIPD.

The study included a hypothetical 25-million-member health plan based on prevalence and IG treatment with an expected 708 patients with CIDP on treatment. Results indicated a budget impact of $45,996,708 (35.5 percent increase) for efgartigimod when assuming a 10 percent uptake of the treatment in year one drawing patient share proportionally from IVIG and SCIG. In an alternative scenario, a 10 percent uptake of efgartigimod alfa in year one drawing patient share exclusively from IVIG led to a projected budget impact of $46,079,091 (35.6 percent increase).